A Respiratory Syncytial Virus (RSV) vaccine is a preventive measure against lower respiratory tract disease caused by RSV, a common respiratory virus that usually results in mild, cold-like symptoms
. The U.S. Food and Drug Administration (FDA) has approved two RSV vaccines for adults 60 years of age and older: Arexvy (RSVPreF3) and RSVpreF (Abrysvo)
. Both vaccines contain a part of the RSV virus and work by causing an immune response that can protect against respiratory disease
. The CDC recommends adults 60 years of age and older have the option to receive a single dose of RSV based on discussions between the patient and their healthcare provider
. The vaccines are given as a single dose and can be administered alongside other age-appropriate childhood vaccines
. For infants, there is a long-acting monoclonal antibody called nirsevimab, which can reduce the risk of both hospitalizations and healthcare visits
. This product was developed jointly by pharmaceutical companies Sanofi and AstraZeneca and will be sold under the brand name Beyfortus
. However, nirsevimab is not a vaccine but rather an immunization
. Additionally, there is a vaccine called ABRYSVO from Pfizer, which is a bivalent vaccine and the first-ever RSV vaccine approved for use in the U.S
. Both vaccines have been shown to be effective in reducing the risk of developing RSV-related lower respiratory tract disease
